Drugs / siCoV/KK46
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05208996 | Jan → Mar 2021 | COVID-19 | National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | siCoV/KK46 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05208996 ↗ |
| Action | Inhibit | “SARS-CoV-2 inhibition with siCoV/KK46” NCT05208996 ↗ |
| Modality | Small interfering RNA (siRNA) | “anti-SARS-CoV-2 siRNAs/KK-46” NCT05208996 ↗ |